

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain), September 6, 2018

RELEVANT FACT

Dear Sir,

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") submits hereafter press release on the launch in collaboration with Kimia Farma, of Remikaf, a last generation anesthetic in Indonesia.

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre SA

Important breakthrough in Southeast Asia

REIG JOFRE LAUNCHES IN COLLABORATION WITH KIMIA FARMA,
REMIKAF, A LAST GENERATION ANESTHETIC IN INDONESIA

- Agreement signed with Kimia Farma to market in Indonesia Remikaf, a state-of-the-art anesthetic based on remifentanyl, an innovative compound for physicians in Indonesia
- Reig Jofre presented Remikaf at the annual conference of anesthesia specialists KPPIA Perdatin 2018 (Kursus Penyegaran dan Penambah Ilmu Anesthesia) held in Surabaya, East Java, Indonesia
- After the opening of the markets of Japan in 2016 and the Philippines in 2017, Reig Jofre goes one step further in its strategic internationalization plan with the opening of the Indonesian market in 2018 which, with more than 260 million inhabitants, is the fourth most populated country in the world. Asia and Oceania remain strategic geographic areas for the company, representing 11% of sales in 2017

Barcelona (Spain), September 6, 2018. The pharmaceutical companies Reig Jofre and Kimia Farma start the sales and marketing after having signed an agreement in 2015 to distribute **Remikaf**, innovative anesthetic in Indonesia, after a registration process of more than three years, subject to complex regulatory requirements regarding its manufacture, import and distribution.

The state-owned company Kimia Farma is the only local pharmaceutical company licensed to import and distribute controlled substances in Indonesia, a very strict country in the import of medicines. The Republic of Indonesia, composed of more than 14,000 islands and a population of over 260 million inhabitants, is the fourth most populous country in the world and represents 50% of the population of the ASEAN region.

Currently, Reig Jofre manufactures 30% of the world's supply of injectable vials of remifentanyl, the active ingredient of Remikaf, at the injectable plant of Barcelona. The development of this finished product in vial formulated and stabilized by the lyophilization process was carried out by the company's R&D team and has now been launched in more than 30 countries.



Reig Jofre presented Remikaf with the help of the expert, Miriam de Nadal, MD., PhD Clinical Head of the Anesthesiology, Surgical Intensive Care Unit of the University Hospital Vall d'Hebron of Barcelona (Spain), at the annual congress of anesthesia specialists KPPIA Perdatin 2018 (Kursus Penyegaran dan Penambah Ilmu Anesthesia) recently held in Surabaya, East Java, Indonesia, a must for the more than 2000 specialists in anesthesia of the Asian country.

Remikaf is a state-of-the-art psychotropic for hospital use, ultra-short-acting that provides the hemodynamic stability necessary for optimal control of anesthesia in surgical procedures that does not accumulate, which allows rapid recovery of the patient in the post-operative period.

Thanks to its metabolization by enzymes of blood plasma, Remikaf can be administered in patients with kidney failure or liver disease, without the need of dose adjustment.

This agreement is of additional value to Reig Jofre since it will open new business opportunities in the Southeast Asia market for the commercialization of this anesthetic, as well as the introduction of other product ranges with the aid of Kimia Farma, who holds the largest market share in the area for the import and distribution of psychotropic products and a significant share on hospital setting for the rest of pharmaceutical products.

The agreement with Kimia Farma joins the creation in 2015 of Reig Jofre Europe, a joint venture in Singapore for the marketing of Reig Jofre products in Southeast Asia and the agreement formalized in 2015 with the Japanese Maruishi Pharma to market state-of-the-art injectables for hospital use in Japan. All of them examples of Reig Jofre's commitment to internationalization as one of its strategic pillars, with Asia and Oceania, key markets due to their size and growth potential.

Receive Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **www.reigjofre.com**

About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a pharmaceutical company focused on the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre directs its R&D to the development of new formulations and indications in the therapeutic areas of (dermatology, respiratory/ENT, gynecology); to the development of innovative molecules in collaboration with research start-ups or knowledge centers in either the technological specialization areas of (injectable products and beta-lactam antibiotics) or the therapeutic areas; and to the development of generic medicines of technological specialization. Reig Jofre has over 900 employees, 4 development and manufacturing centers in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and over 130 commercial partners in 67 countries worldwide. The company reached sales of €168 M in 2017. Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 65,050,067 shares



For further information

Media

Inma Santa-Pau

Tel. (+34) 93 480 67 10 – ext. 1242 | inma.santapau@reigjofre.com

Shareholder office

Patricia Casado

Tel. (+34) 93 480 67 10 – ext. 1237 | patricia.casado@reigjofre.com